Serum tumour necrosis factor-α and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome

Acta Neurologica Scandinavica

Volumn 109, Issue 1, 2004, Pages 71-74

  Radhakrishnan, V V ^a   Sumi, M G ^a   Reuben, S ^a   Mathai, A ^a   Nair, M D ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

Guillain Barre syndrome; Intravenous immunoglobulins; Plasma exchange; Soluble tumour necrosis factor receptor I; Soluble tumour necrosis factor receptor II; Tumour necrosis factor

Indexed keywords

IMMUNOGLOBULIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GUILLAIN BARRE SYNDROME; HOSPITAL ADMISSION; HUMAN; PLASMAPHERESIS; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

BIOLOGICAL RESPONSE MODIFIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; PLASMA EXCHANGE; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0742286858     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2003.00179.x     Document Type: Article

References (15)

1. HUGHES RAC, ATKINSON P, WATES P et al. Sural nerve biopsies in Guillain-Barre syndrome; axonal degeneration and macrophages, associated demyelination and absence of cytomegalovirus genome. Muscle Nerve 1992;15:568-75.
2. SCHMIDT B, TOYKA KV, KIEFER R et al. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996;19:474-87.
3. REES SH, GRISON NA, HUGHES RAC. Anti-ganglioside GM1 antibodies in Guillain-Barre syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995;38:809-16.
4. SHARIEF MIK, MC LEAN B, THOMPSON EJ. Elevated serum levels of tumour necrosis factor alpha in Guillain-Barre syndrome. Ann Neurol 1993;33:591-6.
5. SELMAJ KW, RAINE CS. Tumour necrosis factor mediates myelin and oligodendrocyte damage in-vitro. Ann Neurol 1988;23:339-46.
6. ASBURY AK, CORNBLATH DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990;27:21-24.
7. HUGHES RAC, NEWSEN DAVIS J, PERKIN G. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2: 750-3.
8. HOHMANN H, REMY R, BROCKHAUUS M, VAN LOON APGM. Two different cell type have different major receptors for human tumour necrosis factor alpha. J Biol Chem 1984; 264:14927-34.
9. LOETSCHER H, STEMNETZ M, LESSLAUER W. Tumour necrosis factor: receptors and inhibitors. Cancer Cells 1991;3:221-6.
10. ADERKA D, ENGLEMAN H, MAOR Y, BRAKEBUSCH, WALLACH D. Stabilization of the bioactivity of human tumour necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
11. SHARIEF MK, INGRAM MB, SWASH M, THOMPSON EJ. Immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology 1999;52:1833-8.
12. H 1 cytokines are augmented systematically early in Guillain-Barre syndrome. Neurology 2002;58:476-88.
13. OSSEGE LM, SINDERN E, VOSS B, MALIN JP. Expression of TNF and TGF1 in Guillain-Barre syndrome: correlation of a low TNF-/TGF1-mRNA ratio with good recovery and signs for immunoregulation within the cerebrospinal fluid compartment. Eur J Neurol 2000;7:17-25.
14. MA JJ, NISHIMURA M, MINE BS et al. Genetic contribution of tumor necrosis factor region in Guillain-Barre syndrome. Ann Neurol 1998;44:815-8.
15. CREANGE A, BELEC L, CLAIR B, RAPHEAL JC, GHERADI RK. Circulating tumour necrosis factor alpha (TNFa) and soluble TNF factors in patients with Guillain-Barre Syndrome. J Neuroimmunol 1996;68:95-99.